Louisa Hoes
Cancers will increasingly meet the definition of ‘rare’ in terms of the molecular profiles that make each tumor unique. The more research we can do into this, the better we will be able to offer patients personalized treatment in the future. Whole Genome Sequencing and studies like DRUP are making an important contribution to this.
Back to newsMore news
Whole genome sequencing: the future of molecular diagnostics in gynecological cancer?
To mark Gynecological Oncology Awareness Month, we spoke with oncologist Eelke Gort about the role of molecular diagnostics in these …
Dutch House of Representatives votes for action of the Minister for arranging (provisional) reimbursement for whole genome sequencing-based DNA testing for most urgent groups of cancer patients
On February 25 2021, the Dutch House of Representatives adopted a motion approving reimbursement on a provisional basis of a …
ASCO 2021: Presentations about whole genome sequencing
At the congress of the American Society of Clinical Oncology (ASCO) on 4-8 June 2021 researchers Kris Samsom and Luuk …
Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing.